NASDAQ
12.50USD
-0.10 (-0.79%)
We have scored 11 news catalysts on BrainsWay Ltd. (BWAY) over the past 12 months. The biggest single-day move next to one of them came Dec 23, 2025, when BWAY closed +4.4%: “BWAY Shares Gain on Optum Expanding Deep TMS Coverage for Teens”. Coverage across the window leans positive (average ticker sentiment +0.72). Most of the impact sits in price momentum and earnings revision trend.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
490.3M
P/E
—
EPS
—
Beta
0.15
52W range
7.135-17.4
Day range
12.45–12.96
Open
12.59
Prev close
12.60
Volume
50.8K
Avg volume
112.3K
Dividend
0.00
IPO
2019-04-17
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about BrainsWay Ltd. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for BWAY: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
